SEARCH

SEARCH BY CITATION

References

  • 1
    Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35: 495516.
  • 2
    Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 13919.
  • 3
    Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol 2005; 84: 62739.
  • 4
    Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004; 23: 293449.
  • 5
    Chen GQ, Wang LS, Wu YL, Yu Y. Leukemia, an effective model for chemical biology and target therapy. Acta Pharmacol Sin 2007; 28: 131624.
  • 6
    Li QY, Zu YG, Shi RZ, Yao LP. Review camptothecin: current perspectives. Curr Med Chem 2006; 13: 202139.
  • 7
    Bomgaars L, Berg SL, Blaney SM. The development of camptothecin analogs in childhood cancers. Oncologist 2001; 6: 50616.
  • 8
    Song MG, Gao SM, Du KM, Xu M, Yu Y, Zhou YH, et al. Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms. Blood 2005; 105: 371421.
  • 9
    Liu W, Zhu YS, Guo M, Yu Y, Chen GQ. Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia. Leuk Res 2007; 31: 156574.
  • 10
    Yu Y, Wang LS, Shen SM, Xia L, Zhang L, Zhu YS, et al. Subcellular proteome analysis of camptothecin analogue NSC606985-treated acute myeloid leukemic cells. J Proteome Res 2007; 6: 380818.
  • 11
    Han YH, Xia L, Song LP, Zheng Y, Chen WL, Zhang L, et al. Comparative proteomic analysis of hypoxia-treated and untreated human leukemic U937 cells. Proteomics 2006; 6: 326274.
  • 12
    Jin X, Xia L, Wang LS, Shi JZ, Zheng Y, Chen WL, et al. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics 2006; 6: 194856.
  • 13
    Mukherji M. Phosphoproteomics in analyzing signaling pathways. Expert Rev Proteomics 2005; 2: 11728.
  • 14
    Sonobe S, Takahashi S, Hatano S, Kuroda K. Phosphorylation of Amoeba G-actin and its effect on actin polymerization. J Biol Chem 1986; 261: 1483743.
  • 15
    Kwiatkowska K, Sobota A. Engagement of spectrin and actin in capping of FcgammaRII revealed by studies on permeabilized U937 cells. Biochem Biophys Res Commun 1999; 259: 28793.
  • 16
    Janmey PA. The cytoskeleton and cell signaling: component localization and mechanical coupling. Physiol Rev 1998; 78: 76381.
  • 17
    Attard G, Greystoke A, Kaye S, De Bono J. Update on tubulin-binding agents. Pathol Biol 2006; 54: 7284.
  • 18
    Van de Water B, Kruidering M, Nagelkerke JF. F-actin disorganization in apoptotic cell death of cultured rat renal proximal tubular cells. Am J Physiol 1996; 270: F593603.
  • 19
    Chang JY, Hsieh HP, Pan WY, Liou JP, Bey SJ, Chen LT, et al. Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent. Biochem Pharmacol 2003; 65: 200919.
  • 20
    Rao J, Li N. Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets 2004; 4: 34554.
  • 21
    Jackson DN, Foster DA. The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival. FASEB J 2004; 18: 62736.
  • 22
    Basu A. Involvement of protein kinase C-delta in DNA damage-induced apoptosis. J Cell Mol Med 2003; 7: 34150.
  • 23
    Liedtke CM, Hubbard M, Wang X. Stability of actin cytoskeleton and PKC-delta binding to actin regulate NKCC1 function in airway epithelial cells. Am J Physiol Cell Physiol 2003; 284: C48796.